TWO · 7427.TWO
Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
Loading market information…
TAI · 6645.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Kim Forest Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kim Forest Enterprise Co., Ltd.’s forward annual dividend is NT$0.08 per share, paid annual. The forward yield is 0.64% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kim Forest Enterprise Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kim Forest Enterprise Co., Ltd. specializes in advanced precision medical products. The company equips healthcare providers with essential diagnostic devices, reagents, and analytical pipelines, enabling crucial screening tests for conditions such as cancer and inherited diseases. Its comprehensive portfolio extends to supporting cancer patients through genetic testing services, personalized drug reports, and monitoring tools. Furthermore, it caters to healthy individuals by offering non-invasive, genome-wide health assessments. Kim Forest also delivers specialized bioinformatics service items, prenatal test kits, and genetically modified models. Notably, its product range also includes SARS-CoV-2 detection kits. Established in 2004, the company is headquartered in New Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NT$96.44M-0.58% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$19.70-NT$0.60 (-2.96%)
Anxo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.57% below the high.
NT$23.00NT$0.00 (0.0%)
LabTurbo Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.88% below the high.
NT$13.80-NT$0.20 (-1.43%)
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
NT$23.20-NT$0.50 (-2.11%)
Excelsior Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
NT$36.05-NT$0.85 (-2.3%)
Genetics Generation Advancement Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.32% below the high.
NT$15.40-NT$0.65 (-4.05%)
AmCad BioMed Corporation’s quoted price sits in the upper half of its reported 52-week range, 18.3% below the high.
NT$6.40-NT$0.31 (-4.62%)
Holy Stone Healthcare Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.32% below the high.
